Steven S. Tau

This study shows endocrine therapy induces oxidative stress in ER+ breast cancer cells, making them more susceptible to ferroptosis, suggesting a new therapeutic strategy.

This study identifies mitochondrial oxidative phosphorylation as a metabolic vulnerability in endocrine-tolerant persister ER+ breast cancer cells, suggesting therapeutic targeting of mitochondrial function could prevent recurrence.